1-4 of 4
Jacob D. Jaffe
Close
Sort by
Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Clinical Trials & Observations
Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D. Jaffe, Sara N. Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David Weaver, Francine M. Foss, David M. Weinstock
Journal: Blood
Blood (2018) 131 (8): 888–898.
https://doi.org/10.1182/blood-2017-08-802470
Published: 2018
Includes: Supplemental data
Journal Articles

Impact of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia on Signaling and Epigenetics in Endothelial Cells

Srila Gopal, Qing Lu, MD PhD, Wendy Baur, Sitara Rao, Lev Litichevskiy, Malvina Papanastasiou, Amanda Creech, Adam Officer, Shawn Egri, Desiree Davison, Jacob D Jaffe, PhD, Iris Zamir Jaffe, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2296.
https://doi.org/10.1182/blood.V130.Suppl_1.2296.2296
Published: 2017
Journal Articles

The Impact of Chemotherapeutic Agents on Signaling and Epigenetics in Vascular Endothelial Cells

Srila Gopal, MD, Amanda Creech, Adam Officer, Shawn Egri, Desiree Davison, Jacob D Jaffe, PhD, Iris Z Jaffe, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1353.
https://doi.org/10.1182/blood.V128.22.1353.1353
Published: 2016
Journal Articles

Conditional Deletion of Asxl1 Results in Myelodysplasia

Omar Abdel-Wahab, M.D., Jie Gao, PhD, Mazhar Adli, PhD, Young Rock Chung, MSc, Richard Koche, PhD, Alan H. Shih, MD, PhD, Suveg Pandey, BSc, Lindsay M. La-Fave, PhD, Delphine Ndiaye-Lobry, Yu Sup Shin, BSc, Parva K. Bhatt, BSc, Jay P. Patel, Xinyang Zhao, PhD, Christopher Y. Park, MD, PhD, Jacob D. Jaffe, PhD, Bradley E. Bernstein, MD, PhD, Iannis Aifantis, PhD, Ross L. Levine
Journal: Blood
Blood (2012) 120 (21): 308.
https://doi.org/10.1182/blood.V120.21.308.308
Published: 2012